Search





Search





Markets
/
Stocks
/
zbio
/

Zenas Biopharma Inc

ZBIO

Add to Watchlist

31.440USD

-0.830-2.57%

Close 07-31 16:00（ET）Quotes delayed by 15 min

1.98BMarket Cap

LossP/E TTM

Zenas Biopharma Inc

31.440

-0.830-2.57%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

-2.57%

5 Days

+3.46%

1 Month

+12.29%

6 Months

+71.15%

Year to Date

-13.41%

1 Year

+104.02%

Key Figures

32.690Open

32.950High

452.23KVolume

LossP/E TTM

LossP/E Dynamic

--Dividend TTM

0.83%Turnover Ratio

32.270Prev. Close

30.600Low

10.88MTurnover

LossP/E Static

7.07P/B

0.00%Div Yield TTM

-78.63%ROA

44.60052wk High

0.60Volume Ratio

-156.99MNet Profit

54.49MShares

-9.0976EPS TTM

--Beta

-137.11%ROE

8.91052wk Low

7.28%Amplitude

100.00%Gross Margin

1.98BMarket Cap

4.08Reward/Risk

5.39%Risk Rate

TradingKey Stock Score of Zenas Biopharma Inc

Currency: USD Updated: 2026-07-31

Key Insights

Zenas Biopharma Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 46 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 43.50.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Zenas Biopharma Inc's Score

Industry at a Glance

Industry Ranking

46 / 385

Overall Ranking

117 / 4281

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Zenas Biopharma Inc Highlights

StrengthsRisks

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.00M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 10.00M.

Undervalued

The company’s latest PE is -3.46, at a low 3-year percentile range.

Held by Bill Nygren | OAKMX

Star Investor Bill Nygren | OAKMX holds 1.29K shares of this stock.